Sciact
  • EN
  • RU

Global burden of vision impairment due to age-related macular degeneration, 1990–2021, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021 Full article

Journal The Lancet
ISSN: 0140-6736
Output data Year: 2025, Volume: 13, Number: 7, Pages: e1175-e1190 Pages count : DOI: 10.1016/s2214-109x(25)00143-3
Authors Artamonov Anton Anatolʹevich 1,2
Affiliations
1 GBD 2021 Global AMD Collaborators
2 IBMP RAS

Abstract: Globally, the number of individuals with vision impairment due to AMD more than doubled, rising from 3·64 million (95% uncertainty inverval [UI] 3·04–4·35) in 1990 to 8·06 million (6·71–9·82) in 2021. Similarly, DALYs increased by 91% over the same period, from 0·30 million (95% UI 0·21–0·42) to 0·58 million (0·40–0·80). By contrast, age-standardised prevalence and DALY rates declined, with prevalence rates decreasing by 5·53% (99·50 per 100 000 of the population [95% UI 83·16–118·04] in 1990 to 94·00 [78·32–114·42] in 2021) and DALY rates dropping by 19·09% (8·38 [5·70–11·53] to 6·78 [4·70–9·32]). These rates showed a consistent decrease in higher SDI quintiles, reflecting the negative correlation between HAQ Index and AMD burden. A general downward trend was observed from 1990 to 2021, with the largest age-standardised reduction occurring in the low-middle SDI quintile. The global contribution of tobacco to age-standardised DALYs decreased by 20%, declining from 12·45% (95% UI 7·73–17·37) in 1990 to 9·96% (6·12–14·06) in 2021. By 2050, the number of individuals affected by AMD is projected to increase from 3·40 million males (95% UI 2·81–4·17) in 2021 to 9·02 million (5·72–14·20) and from 4·66 million females (3·88–5·65) to 12·32 million (8·88–17·08). Eliminating tobacco use could reduce these numbers to 8·17 million males (5·59–11·92) and 11·15 million females (8·58–14·48) in 2050. Общее число авторов 372
Cite: Artamonov A.A.
Global burden of vision impairment due to age-related macular degeneration, 1990–2021, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021
The Lancet. 2025. V.13. N7. P.e1175-e1190. DOI: 10.1016/s2214-109x(25)00143-3 WOS Scopus РИНЦ OpenAlex
Identifiers:
Web of science: WOS:001525587200001
Scopus: 2-s2.0-105008914096
Elibrary: 84316640
OpenAlex: W4411636414
Citing:
DB Citing
OpenAlex 54
Altmetrics: